Windtree Therapeutics, Inc. (NASDAQ: WINT) is engaged as a biotechnology company, which is focused on late-stage treatments for cardiovascular disorders.
Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
December S&P 500 futures (ESZ22) are trending lower -1.15% this morning, erasing yesterday’s gains after three major US benchmark indices bounced back sharply during the regular session as risk appetite...
Positive Data for Istaroxime in Early Cardiogenic Shock Brings Notable Interest from Potential Partners WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE)...
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours with the istaroxime group performing significantly better...
Company to host conference call following the presentation...
Monday U.S. Economic Lookahead Factory orders (Feb.) Featured Earnings Silverback Therapeutics ...
Company to present on Monday, April 4, 2022 at 11:00 am...
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple...
Results support the feasibility for development of a potential treatment for critically ill patients with ARDS due to COVID-19 and other causes...